Yu.S. Vaganova

Yu.S. Vaganova

Auto-generated profile, based on publicly available information

Yu.S. Vaganova

Pavlov First Saint Petersburg State Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Russian neurological Journal
Verified
Journal Article
Closed access
PDF file
AAA. V. Amelin
A. V. Amelin
SSSokolov Sokolov
Sokolov Sokolov
YVYu. S. Vaganova
Yu. S. Vaganova
This article deals with new migraine therapy, monoclonal antibodies against calcitonin gene related peptide (CGRP) and its receptor. The review represents a brief discussion of CGRP biological eff ects in the peripheral and central nervous system, and the role of CGRP in the migraine pathogenesis. Data of systematic reviews of randomized clinical research about the effi cacy and safety of monoclonal antibodies against CGRP (fremanezumab, eptinezumab and galkanezumab) and its receptor (erenumab) in patients with episodic and chronic migraine are included and analyzed. The results of fi ve-year use of erenumab in clinical research and in real practice are discussed and compared.

18 August 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AAA. V. Amelin
A. V. Amelin
IVI. S. Vaganova
I. S. Vaganova
MKM. I. Koreshkina
M. I. Koreshkina
NTN. M. Tereshchenko
N. M. Tereshchenko
Introduction. Migraine is a common disabling condition. Migraine patients require fast-acting drugs with high efficacy. Prior studies have demonstrated that zolmitriptan oral dosage forms (oral tablets) are highly effective in the treatment of migraine attacks.Aim. To evaluate the efficacy, timing of onset of therapeutic effect and tolerability of zolmitriptan nasal spray (Xsenza®) in the treatment of migraine.Materials and methods. A total of 39 patients aged 20 to 58 years with migraine were enrolled in a prospective, multicentre, observational study. Patients were included in a group to treat three consecutive migraine attacks with zolmitriptan nasal spray at a dose of 2.5 mg according to their habitual behaviour model that most closely reflects clinical practice. Efficacy endpoint (positive attack treatment outcome) was the generally accepted measure of reduction in cephalalgia intensity and concomitant autonomic symptoms (reduction in pain and autonomic symptoms from severe/moderate to mild/absence severity according to VAS) 2 hours after zolmitriptan inhalation.Results. The absence or mild intensity of headache was reported in 25% of patients 10 minutes (earliest assessment in that study) and in 28% of patients 30 minutes after administration of the drug. The proportion of patients with positive treatment outcomes in all three consecutive migraine attacks two hours after administration of zolmitriptan nasal spray 2.5 mg was 69.2%, 75% and 75%, respectively. Zolmitriptan nasal spray was well tolerated, while most adverse events were mild in severity and transient in nature.Conclusions. Zolmitriptan nasal spray (Xsenza®) is highly effective in the treatment of migraine attacks and has a rapid onset of action. The drug combines high efficacy and good tolerability.

6 October 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
GPG.V. Ponomarev
G.V. Ponomarev
YVYu.S. Vaganova
Yu.S. Vaganova
AAA.V. Amelin
A.V. Amelin
ASA.A. Skoromets
A.A. Skoromets
Objective. To identify and detail the main causes of late diagnosis of vascular myelopathy. Material and methods. A retrospective and prospective study of 77 patients diagnosed with vascular myelopathy (G95.1) treated at Pavlov University between 2020 and 2024 was conducted. The diagnosis was made after a comprehensive examination and exclusion of other compression and non-compression causes of myelopathy. After the diagnosis was verified, patients were divided into two groups: Group 1 (n=21, 27.3%) included patients admitted with a previously diagnosed vascular myelopathy, and Group 2 (n=56, 72.7%) included patients admitted with a different, incorrect diagnosis. Results. It was found that 27 patients (48.2%) of Group 2 and 1 patient (4.8%) of Group 1 (p=0.0004, OR=18.62, 95% CI 2.34—148.4) were not hospitalized in the first three days from the onset of the disease in a facility equipped with the necessary laboratory and instrumental equipment to establish the cause of myelopathy. Thirty (53.6%) patients in Group 2 had significant deviations in the primary interpretation of the medical history and clinical presentation, whereas in Group 1, such deviations were detected in 1 (4.8%) patient (p<0.0001, OR=23.1, 95% CI 2.89—183.9). MRI was not performed in the first three days after admission to the hospital in 47 (90.4%) patients of Group 2 and 9 (45.0%) patients in Group 1 (p<0.0001, OR=11.5, 95% CI 3.21—41.12). Patients with an incorrect diagnosis had a significantly severe disability (p<0.001), while patients with a correct diagnosis demonstrated better functional independence (p<0.001). Conclusion. Three groups of causes of late diagnosis of vascular myelopathy were identified: related to the delay in medical care and patient routing, incorrect interpretation of the history and clinical presentation, and late neuroimaging. To improve the quality of care, it is necessary to raise awareness of the clinical manifestations and modern methods for diagnosing spinal cord infarction, ensure the accessibility of the necessary diagnostic tests, and improve patient routing.

24 June 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
AAA. V. Amelin
A. V. Amelin
YVYu. S. Vaganova
Yu. S. Vaganova
NKN. A. Kovalchuk
N. A. Kovalchuk
YTYu. V. Trinitatskiy
Yu. V. Trinitatskiy
ELE. A. Lyakhova
E. A. Lyakhova
Pharmacological treatment of tension-type headache (TTH) attacks involves the selection of the most effective and safe analgesic. However, the choice of medication is limited by the insufficient number of evidence-based studies for this type of headache (HA).Objective: to evaluate the efficacy, safety, and tolerability of fast-release lornoxicam (Xefocam rapid) compared to standard lornoxicam (Xefocam), naproxen, and ibuprofen in relieving headache episodes in patients with frequent episodic TTH in routine clinical practice.Material and methods. The multicenter, observational (non-interventional), prospective RAPID study was conducted in 10 clinical centers across the Russian Federation and included 400 adult patients (74.5% women, 25.5% men) aged 18 to 76 years (mean age: 39.83±12.58 years) with frequent episodic TTH who were prescribed one of the following NSAIDs in routine practice: Xefocam, Xefocam rapid, ibuprofen, or naproxen. The following outcomes were assessed: the number of completely relieved TTH episodes, changes from baseline in the mean number of headache days, mean number of TTH episodes per month, mean duration of TTH episodes, and mean pain intensity on a numerical rating scale, time from drug intake to partial and complete relief of a TTH episode, mean number of days with intake of the drugs in question, number of patients using NSAIDs ≥15 days per month, number of patients taking additional medications for TTH relief, patient satisfaction with the prescribed treatment, number of patients who discontinued treatment, and the frequency of adverse events during therapy.Results. The study demonstrated overall high efficacy of Xefocam and Xefocam rapid in relieving TTH attacks. At the same time, the data obtained allow the identification of some priority effects of investigated drugs. Thus, Xefocam and Xefocam rapid showed the highest efficacy in achieving complete headache relief within 2 hours after intake. Moreover, Xefocam rapid was the most effective across all groups in achieving complete headache relief within the first 30 minutes. The greatest reduction in the numerical rating scale (NRS) score was also observed in the Xefocam rapid and Xefocam groups. In addition, Xefocam and Xefocam use demonstrated the lowest need for additional medications for pain relief among all groups, which may be related to the rapid onset of analgesic action and high safety profile of these drugs. Patients in the Xefocam rapid group more frequently rated their satisfaction with the therapy as excellent.Conclusion. Xefocam rapid showed a high safety profile and excellent tolerability, with the lowest incidence of adverse events among all study groups.

30 October 2026 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
GPG. V. Ponomarev
G. V. Ponomarev
YVYu. S. Vaganova
Yu. S. Vaganova
AAA. V. Amelin
A. V. Amelin
ASA. A. Skoromets
A. A. Skoromets
Spinal cord infarction (SCInf, vascular myelopathy) accounts for 1‑2 % of all vascular neurological events, yet its differential diagnosis from non-ischemic myelopathies remains challenging, particularly in the early stages of the disease. The aim of this study was to evaluate the diagnostic significance and prognostic potential of routine complete blood count parameters, markers of carbohydrate and protein metabolism, as well as systemic inflammation markers in patients with verified SCInf, and to determine their possible association with the disease phase and functional outcomes. This single-center combined study included 177 patients: 77 with SCInf (main group) and 100 with non-ischemic myelopathies (comparison group). Clinical and biochemical parameters, inflammatory markers, neurological status assessed by the ASIA scale, and functional outcomes evaluated by the modified Rankin Scale were analyzed. Patients with SCInf demonstrated significantly higher levels of leukocytes (7.2×10⁶ / L in the main group and 6.45×10⁶ / L in the comparison group, p=0.009), erythrocyte sedimentation rate (14.0 and 9.0 mm / h, p=0.002), glucose (5.70 and 4.95 mmol / L, p<0.0001), glycated hemoglobin (5.5 and 5.0 %, p=0.0007), urea (6.11 and 4.93 mmol / L, p=0.003), and C-reactive protein (4.07 and 1.8 mg / L, p0.05). The most pronounced changes were observed in the acute phase of vascular myelopathy. Unfavorable functional outcome was associated with higher levels of glucose, urea, C-reactive protein and lower hematocrit and total protein values. These findings demonstrate that SCInf is accompanied by activation of the systemic inflammatory response and metabolic disturbances, and that routine laboratory parameters may be used for risk stratification of unfavorable outcomes.

3 October 2022 in Russian neurological Journal
Verified
Journal Article
Closed access
PDF file
ISIa. B. Skiba
Ia. B. Skiba
SSSokolov Sokolov
Sokolov Sokolov
YVYu. S. Vaganova
Yu. S. Vaganova
EGE. V. Goncharova
E. V. Goncharova
APAlexey Polushin
Alexey Polushin
AKAlexander Kulagin
Alexander Kulagin
The aim of the study was to assess the incidence and clinical features of headache associated with the use of granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization or neutropenia treatment among oncohematological patients and bone marrow donors.Material and methods. A prospective observational uncontrolled study included 39 participants: 20 bone marrow donors (group 1) and 19 oncohematological patients (group 2). We evaluated the incidence and clinical features of headache after subcutaneous administration of G-CSF (filgrastim) at doses of 5 to 10 μg/kg for 2 to 5 days.Results. Headache occurred in bone marrow donors more often compared to patients with hematological malignancies (78.9% vs 35.0%; p = 0.006). There were no significant differences in the time of headache onset, its duration, intensity, features, and localization between two groups. Gender, age, dose of G-CSF, and duration of its use were not associated with headache development in both groups.Conclusion. Headache occurs more often in bone marrow donors than in patients with hematological malignancies. The phenotype of headache associated with G-CSF exposure is not drug-specific and requires further studies on its semiotics.